Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beam TherapeuticsBEAM -3.17%70 10-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus rates BEAM with a GF Score™ of 70/100 and a GF Value™ of $25.37 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 667 Biotechnology companies, Beam Therapeutics ranks worse than 149924.89% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Beam Therapeutics's current 10-Year Share Buyback Ratio was 0.00%.
BEAM's 10-Year Share Buyback Ratio is not ranked *
in the Biotechnology industry.
Industry Median: -11.6 * Ranked among companies with meaningful 10-Year Share Buyback Ratio only.
Beam Therapeutics (NAS:BEAM) 10-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Beam Therapeutics 10-Year Share Buyback Ratio Related Terms
BEAM vs KOD, TARS, VERA: 10-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Beam Therapeutics's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics 10-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's 10-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's 10-Year Share Buyback Ratio falls into.
Beam Therapeutics 10-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 10-Year Share Buyback Ratio of 0.00 mean?
Beam Therapeutics (BEAM) has a 10-Year Share Buyback Ratio of 0.00 as of Jun. 2026. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Beam Therapeutics and its competitors. According to the industry distribution chart, Beam Therapeutics ranks #999999 out of 667 companies in the Biotechnology industry.
Is Beam Therapeutics' 10-Year Share Buyback Ratio too high?
Beam Therapeutics' current 10-Year Share Buyback Ratio is 0.00. Based on the distribution chart, Beam Therapeutics ranks #999999 out of 667 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Beam Therapeutics has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' 10-Year Share Buyback Ratio compare to KOD and TARS?
According to the Biotechnology industry distribution chart, Beam Therapeutics ranks #999999 out of 667 companies for 10-Year Share Buyback Ratio. This places Beam Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Biotechnology company?
A good 10-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Beam Therapeutics and its competitors. Beam Therapeutics's current 10-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is $25.37, compared to a current price of $30.05 — trading 18.4% above its estimated fair value. The current 10-Year Share Buyback Ratio is 0.00. Beam Therapeutics' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Beam Therapeutics (BEAM), the current 10-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued.
The current stock price of $30.05 is trading 18.4% above its estimated GF Value™ of $25.37.
GuruFocus considers Beam Therapeutics to be Modestly Overvalued.
Key valuation signals for BEAM:
10-Year Share Buyback Ratio: 0.00
GF Value™: $25.37 vs. price of $30.05 (18.4% above fair value)
No single metric tells the full story. See the BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
70GF Score
Get the complete analysis for BEAM
10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BEAM has been successfully added to your 
